Fusion Antibodies plc (FAB.L) LSE
Currency In GBp
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In GBp
Address
1 Springbank Road
Belfast, BT17 0QL
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 28 9043 2800
Sector
Healthcare
Industry
Biotechnology
Employees
27
First IPO Date
December 18, 2017
| Name | Title | Pay | Year Born |
| Adrian Kinkaid | Chief Executive Officer & Director | 219,000 | 1967 |
| Richard John Buick | Chief Scientific Officer & Director | 156,000 | 1976 |
| Stephen Smyth | Company Secretary, Interim Chief Financial Officer & Director | 0 | 1974 |
| Nicola Hamilton | Operations Manager | 0 | N/A |
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.